Take a look at our previous reports:


Our commitment to Patients (graphic)

We are engaged. Our commitment to developing transformational medicines that create more years of life and quality of life For Patients, With Patients and the healthcare community around the world

We value continuous improvement in our approach to research, development, and healthcare access, with an unwavering focus on outcomes that deliver the greatest value to patients. We embrace change and support disruptive innovation, strive to build a culture of responsible innovation throughout a medicine’s entire lifecycle and are committed to ensuring the safe and appropriate use of our medicines, if approved, as may be prescribed by physicians and used by patients in medical practice.

We focus our development efforts on areas where we have deep expertise and map out the shortest path to market with the objective of reducing the time it takes to bring new medicines to patients.

At every stage of the patient journey, we aim to collaborate closely with patient organizations, beginning in the clinical study design. Through these efforts, we aim to maintain a clear line of communication with patients, having a significant positive impact on their experiences with our studies.

In 2021 we co-developed our Patient Partnership Charter with the patient community to formalize our commitment to patient engagement. Using the Charter as a guideline, we defined our roadmap to integrate patient engagement systematically throughout the medicine lifecycle.

We believe our research and development efforts can help advance science beyond the patients we serve. Our plain-language summaries of our data make them easy to understand, and our commitment to Open Access publishing enables us to communicate clearly and effectively with all our stakeholders.

Furthermore, since 2020, we have been an active member of the Open Pharma initiative, a first-of-its-kind collaborative, multi-sponsor, non-profit project. We believe that publications are the route to credible, compliant pharma communications. Open Pharma’s long-term goal is to secure the same terms for authors who publish company-funded research as those for authors who publish research funded through other means. As such, all research findings are freely available to read and reuse, from the date of publication.

Actions 2023

We have

  • Invested in building up early relationships with patient organizations in relevant therapeutic areas;
  • Co-created the following internal and external, patient focused resources with the Galapagos Patient Engagement Council (PEC) :
    • A standardized list of questions on patient-relevant endpoints;
    • The patients & caregivers page on our corporate website;
    • A dedicated Galapagos job aid focused on assisting colleagues who work with patients;
    • Template letters for patient organizations and sites to communicate time-sensitive information;
  • Systematically embedded the patient and the clinical site expectations into our late phase immunology studies;
  • Rolled out an internal guidance document on how to share study treatments systematically with participants;
  • Written and tested lay summaries of clinical trials’ results with patients for all studies started after June 2022;
  • Maintained strong engagement with relevant patient organizations at key congresses;
  • Involved patient representatives in the steering committees of all our Phase 4 real world evidence studies;
  • Supported the initiatives led by patient organizations during relevant disease awareness days;
  • Held trainings for in-field personnel with patients;
  • Organized the very first Galapagos Patient Partnership Day on 15 November 2023;
  • Incorporated the health literacy principles in our key documents for clinical trial participants;
  • Published plain language summaries in Galapagos driven scientific manuscripts disclosing data from clinical-stage trials;
  • Enabled continued access to Jyseleca® for patients across Europe following the transfer of Jyseleca® and the related commercial activities to Alfasigma; and
  • Begun our efforts to increase patient access through the decentralized CAR-T manufacturing network.
Chimeric antigen receptor T cells (also known as CAR-T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy
The study of the immune system and is a very important branch of the medical and biological sciences. The immune system protects humans from infection through various lines of defence. If the immune system is not functioning as it should, it can result in disease, such as autoimmunity, allergy, and cancer
Jyseleca® is the brand name for filgotinib